AMPLIFY
AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL

Released: December 12, 2024

Expiration: December 11, 2025

Activity

Progress
1
Course Completed